VEGFA and Marinesco-Sjogren syndrome: Notably, the combination of Anti-PD-1 with other agents such as anti-angiogenic drugs, targeted agents, or chemotherapy has shown promise in enhancing the immunological response in MSS CRC patients (16).For instance, the CAPability-01 trial investigated the combination of the PD-1 monoclonal antibody sintilimab with the histone deacetylase inhibitor (HDACi) chidamide, with or without the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab, in patients with unresectable chemotherapy-refractory locally advanced or metastatic MSS/pMMR CRC (17).